Litigation Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)
✉ Email this page to a colleague
ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-04-09 |
| Court | District Court, D. New Jersey | Date Terminated | 2022-01-13 |
| Cause | 15:1126 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Karen M. Williams |
| Parties | NIPPON SHINYAKU CO., LTD. | ||
| Patents | 7,205,302; 8,791,122; 9,284,280 | ||
| Attorneys | ANANDITA VYAKARNAM | ||
| Firms | Windels Marx Lane & Mittendorf, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-04-09 | 1 | infringement of United States Patent No. 7,205,302 (“the ’302 patent”), United States Patent No. 8,791,122 (“the…the ’122 patent”), and United States Patent No. 9,284,280 (“the ’280 patent”) (collectively, “the patents-in-suit… ’302, ’122, and ’280 patents. THE PATENTS-IN-SUIT … assignee of the patents-in-suit. Actelion is an exclusive licensee of the patents-in-suit. …of the ’302 patent is attached as Exhibit A. 87. The ’122 patent was duly and | External link to document | |
| 2021-04-28 | 100 | Letter | collectively, “Zydus”) as to remaining U.S. Patent No. 7,205,302. If the Stipulation and Proposed…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and defendants…against Alembic with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed, and that…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-04-29 | 101 | ~Util - Add and Terminate Parties AND Stipulation and Order | expiration of U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”); and …Plaintiffs and Alembic concerning the ’122 and ’280 patents are dismissed without prejudice, and each party…attorney fees with respect to the ’122 and ’280 patents; 2. The case caption should be…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-06-04 | 19 | Text of Proposed Order | PageID: 277 one or more claims of U.S. Patent Nos. 8,791,122 and 9,284,280 are not invalid and/or unenforceable…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-01-25 | 88 | Letter | proceed against Zydus as to remaining U.S. Patent No. 7,205,302. These stipulations do not concern…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and certain …collectively, “Zydus”) with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed. The Lawsuit…VGYAAN”), which had involved only the ’122 and ’280 patents, will be voluntarily dismissed from the Lawsuit…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
